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Abstract
Background: Impaired glucose regulation (IGR) and hyperlipidemia (HL) are associated with an increased risk of
developing a cardiovascular disease. Hyperlipidemic patients were shown to bear a greater risk for an increased
intima media thickness (IMT). However little is known about differences between treated hyperlipidemic patients
(HL) with normal (NGR) or impaired (IGR) glucose regulation.
Methods: We performed a cross-sectional study, involving 96 non-diabetic HL patients with IGR (fasting plasma
glucose of ≥ 100 mg/dl and <126 mg/dl or/and HbA1c-level of ≥ 5.7 and <6.5 %) or with NGR (HbA1c-level of
<5.7 % and a fasting glucose <100 mg/dl). We compared metabolic characteristics and the IMT between the two
groups. Insulin sensitivity in fasting conditions was described by HOMA-IR and QUICKI.
Results: HL-IGR patients were older (57.6 ± 10.4 vs. 49.1 ± 8.7, p < 0.001), had higher carotid IMT measurements (IMT
average: 0.68 ± 0.14 vs. 0.60 ± 0.09, p = 0.002; IMT right: 0.67 ± 0.15 vs. 0.60 ± 0.10, p= 0.013; IMT left: 0.63 vs. 0.57, p =
0.009), as well as a higher chance to exceed a cut-off value of ≥0.8 mm or insignificant stenosis within this investigation
(OR: 3.9, 95 % CI: 1.15-13.22, p= 0.029) compared to HL-NGR-patients. Furthermore HL-IGR patients were characterised by
a higher waist circumference (100.6 ± 10.1 vs. 91.6 ± 13.3, p < 0.001), higher fasting plasma glucose-levels (100.1 ± 10.8 vs.
88.1 ± 6.6, p < 0.001), higher HbA1c concentrations (5.8 ± 0.33 vs. 5.3 ± 0.24, p < 0.001) and C-peptide levels (2.70 vs. 2.10,
p = 0.012). Age and CVD status were in general the only two variables which independently explained IMT.
Conclusion: Our study showed that among patients with treated hyperlipidemia the presence of IGR characterised
subjects who were older and had a significantly higher risk for an increased IMT compared with those maintaining NGR.
Further studies are necessary to evaluate if this specific subpopulation with IGR can benefit from a more strict
multifactorial management and perhaps from an additional early antihyperglycaemic treatment.
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Background
Dyslipidemia is a known risk factor for an increased
carotid intima media thickness [1] and for the develop-
ment of atherosclerosis [2]. There is a positive correl-
ation between blood lipid levels and cardiovascular risk
[3, 4], so antilipidemic treatment is a cornerstone of the
prevention of cardiovascular disease [5].
In addition to dyslipidemia, prediabetes can also be a
risk factor for the development of cardiovascular disease
[6] and can also associate with increasing IMT-values [7].
While studies show that dyslipidemia can increase the
chance of developing prediabetes [8, 9], the “Paris
Prospective study” showed that the combination of pre-
diabetes- or diabetes with high blood lipid values indeed
is a major risk factor for coronary heart disease [10].
However, initiation of pharmacotherapy in prediabetic
patients is nowadays controversial, partly because there
are no data available that show whether the specific
population of treated hyperlipidemic patients with a
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subclinical diabetes (HL-IGR) can benefit from an add-
itional antihyperglycemic treatment.
In summary, while there is a body of evidence that
both dyslipidemia and prediabetes associate with in-
creased cardiovascular risk, little is known yet about
both the metabolic and clinical characteristics of the
specific subpopulation of treated hyperlipidemic patients
with an impaired glucose regulation (HL-IGR) and the
optimal adjustment of lipid- and glucose values in these
patients.
Therefore, the objective of this study is to compare the
clinical- and metabolic characteristics as well as the ca-
rotid intima-media thickness in patients with a treated
hyperlipidemia additionally affected by prediabetes.
Methods
Study participants and experimental procedures
A cross-sectional study, prospectively involving 96 pa-
tients undergoing hyperlipidemia therapy was conducted
between August 2011 and May 2013. The study was
approved by the Ethics Committee of the Medical
University of Vienna (EC No.: 542/2011) and performed
in accordance with the Declaration of Helsinki. All par-
ticipants gave written informed consent.
Patients were recruited from the outpatient depart-
ment of the division of Endocrinology and Metabolism
of the Medical University of Vienna.
To be included in this study, participants had to be
aged between 35 and 75 years and had to have a stable
dyslipidemic treatment according to the ESC/EAS guide-
lines [11] which hadn’t changed in the last three months
before entering the study. Exclusion criteria was either
diagnosed diabetes mellitus type 1 or manifest diabetes
mellitus type 2 (fasting plasma glucose ≥126 mg/dl or
HbA1c ≥ 6.5 % or antihyperglycemic treatment), meta-
bolic disorders (such as diagnosed hereditary dyslipid-
emia), liver diseases other than non-alcoholic fatty liver
disease, e.g. viral hepatitis, HIV, anti-hormonal therapy
in men (e.g. to treat prostate cancer), corticosteroid ther-
apy within eight weeks prior to study commencement,
immune suppression, chronic renal insufficiency, hep-
atotoxic medication and alcohol abuse. Participants were
divided into two groups: one group included 48 treated
hyperlipidemic patients with impaired glucose regulation
(HL-IGR) and a high risk of developing diabetes (fasting
plasma glucose ≥100 mg/dL and <126 mg/dL or HbA1c
≥5.7 and <6.5 %) according to the guidelines of the
American Diabetes association [12]. The other group
included 48 patients with a diagnosed and treated
hyperlipidemia with a normal glucose regulation with
Hba1c-levels <5.7 % and fasting glucose levels <100 mg/
dl (HL-NGR). Participants’ general medical history and
smoking habits were assessed by questionnaire. An-
thropometric data included body weight, height and
waist circumference, which were measured according to
standardized measurements as previously used in other
studies [13]. Blood pressure and heart frequency were
measured on the right arm after a five minute resting
period in a sitting position.
A positive cardiovascular history was recorded if one
of the following existed: history of stroke, peripheral ar-
tery disease, coronary heart disease, myocardial infarc-
tion and angina pectoris.
Insulin resistance (or sensitivity) in fasting conditions
was assessed by HOMA-IR [14] and QUICKI [15]. We
used a cut-off point of ≥0.8 mm for defining the start of
an insignificant atherosclerosis in the carotis-IMT as
previously done in the study of Riccioni et al. [2]
Ultrasound measurements
IMT measurements were performed using high-
resolution B-mode ultrasonography (Acuson XP 128,
Siemens Medical Solutions, USA) using a 9 MHz linear
transducer probe. Measurements were performed in the
distal common carotid artery, 1.5–2 cm proximal to the
carotid bifurcation on the far vessel wall. The IMT was
defined as the distance between the leading edge of the
lumen-intima echo and the leading edge of the media-
adventitia echo. Frozen end-diastolic images of the far
wall were recorded in a longitudinal view of the artery
and three IMT measurements were obtained from each
common carotid artery. For further analyses the average
value of these three measurements was calculated.
All measurements were performed by an experienced
co-investigator (Silvia Charwat-Resl) under supervision
of another co-investigator (Oliver Schlager) blinded to
any additional clinical information.
Laboratory methods
Blood samples were taken after an at least ≥10 h over-
night fasting period. Laboratory tests measured insulin,
C-peptide, fasting plasma glucose, lipid (triglycerides,
HDL, total cholesterol) levels and pro-BNP using inter-
national standard laboratory methods at the certified
Department of Medical and Chemical Laboratory Diag-
nostics (http://www.kimcl.at/). LDL was calculated with
the Friedewald-formula in persons with <400 mg/dl [16].
Statistical analysis
Continuous variables were summarized by means ± stand-
ard deviations (SD), categorical variables by counts and
percentages as not otherwise indicated. For variables,
which weren’t normally distributed, median and inter-
quartile range were stated. Normal distribution of conti-
nous variables was verified by the Shapiro-Wilk-test. The
following four variables were transformed using logarith-
mic transformation (ln[x]): triglycerides, pro-BNP,
Lipoprotein-a and hsCRP as they were strongly right-
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skewed with the lower limit of zero. Group based compar-
isons (i.e. normal glucose tolerance “NGT” vs. impaired
glucose regulation “IGR”) were compared by using stu-
dent’s t-test (or by the Wilcoxon rank sum test if normal-
ity assumption was violated) and Fisher’s exact test,
respectively. The associations between continuous vari-
ables were assessed by Pearson’s product moment correl-
ation. Linear (for continuous outcomes) and linear
regression models were used for multivariable adjustment
(e.g. age and sex).
Statistical analysis was performed with SPSS (V20).
Only bee swarm plots (Fig. 1) were constructed with R
(V3.1.1) and contributed packages [17]. A two-sided p-
value ≤0.05 was considered statistically significant. P-
values were interpreted descriptively and there were no
considerations to adjust for multiplicity in this observa-
tional study.
Results
In the total study population of n = 96 patients with hyper-
lipidemia, n = 26 (27,1 %) showed impaired fasting glucose
(FPG ≥ 100 mg/dl), n = 36 (37,5 %) showed elevated
HbA1c (≥5.7 %). 48 (50 %) subjects were positive of at
least one of both criteria for prediabetes (HL-IGR) and 48
(50 %) subjects weren’t positive of any criteria for predia-
betes and formed the HL-NGR group. A descriptive com-
parison of study participants (HL-IGR vs. HL-NGR) is
provided in Table 1 and shows, that hyperlipidemic pa-
tients additionally affected by subclinical hyperglycemia
were older, showed a higher degree of central obesity (i.e.
waist circumference) and significantly elevated parameters
of carbohydrate metabolism (i.e. HbA1c, glucose, and C-
peptide concentrations) as compared to normoglycemic
hyperlipidemic subjects. Moreover, univariable compari-
sons indicated significantly higher carotid IMT measure-
ments in the subgroup with borderline hyperglycemia
(Fig. 1), as well as a higher chance to exceed a cut-off
value of ≥0.8 mm or insignificant stenosis within this in-
vestigation (OR: 3.9, 95 % CI: 1.15–13.22, p = 0.029). An
analysis of continuous data revealed that age (r = 0.532, p
< 0.001) is related to average IMT measures (Fig. 2). There
was also a weak positive correlation of fasting plasma glu-
cose and IMT-values (r = 0.237, p = 0.029), however this
correlation lost significance when the four patients with
IMT values >0.9 mm were excluded from the statistical
analysis. No association with IMT was observed for lipid
levels (total cholesterol (TC): r = -0.04, p = 0.693; LDL-
cholesterol: r =−0.08, p = 0.455; HDL-cholesterol: r = -0.095,
p = 0.395; ln(Tg): r = 0.17, p = 0.108), pack years of smoking
(r= 0.16, p = 0.188), parameters of body composition (BMI:
r =−0.06, p = 0.683; waist circumference: r = 0.09, p = 0.446)
or insulin sensitivity (QUICKI: r =−0.12, p = 0.313; HOMA:
r = 0.18, p = 0.137). The correlation between waist circum-
ference and HOMA-IR (p < 0.001), as well as the
correlation between waist circumference and QUICKI-test
(p = 0.001) was significant. Additional calculations in a sub-
group with a history of CVD showed significantly higher
IMT levels as compared to those without CVD (IMT aver-
age: 0.72 ± 0.18 vs. 0.62 ± 0.10, p = 0.043; right carotid in-
tima media thickness “right IMT”: 0.7 ± 0.15 vs. 0.62 ± 0.12,
Fig. 1 Comparison of IMT measurements. Bee swarm plot of carotid IMT data in normal glucose tolerant hyperlipidemic patients (NGT) vs.
hyperlipidemic patients affected by impaired glucose regulation (IGR): left side (a), right side (b), average (c). Lines indicate first, second (median)
and third quartiles
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p = 0.035; left carotid intima media thickness “left IMT”:
0.74 ± 0.24 vs. 0.61 ± 0.12, p = 0.098;) as visualized in Fig. 3.
Multivariable models were performed to adjust for potential
confounding effects of age, sex, glucose and waist
circumference: Age and CVD status were the only variables
which independently explained IMT. The statistical correl-
ation between CVD status and HL-IGR or HL-NGR was
analyzed using the Chi-squared-test and wasn’t significant
Table 1 Characteristics of the study sample
n (NGT/IGR) NGT IGR p-value
Age [years]a 48/48 49.1 ± 8.7 57.6 ± 10.4 <0.001
sex [m]b 48/48 33 (68.8) 29 (60.4) 0.522
BMI [kg/m2]a 45/47 27 ± 4.4 28.4 ± 4.1 0.102
Waist [cm]a 41/45 91.6 ± 13.3 100.6 ± 10.1 <0.001
SBP [mmHg]a 32/34 127.2 ± 10.7 132.7 ± 18.2 0.132
DBP [mmHg]a 32/34 80.8 ± 8.8 80.1 ± 11.2 0.764
TC [mg/dl]c 48/48 214.5 (181.5–273.0) 217.5 (183.5–272.8) 0.980
LDL-C [mg/dl]c 46/45 116.4 (95.8–168.5) 120.0 (98.0–169.1) 0.730
HDL-C [mg/dl]c 46/44 45.5 (38.5–63.0) 49.0 (38.3–61.0) 0.878
NHDL-C [mg/dl]c 46/44 159.0 (130.5–204.8) 158.0 (134.0–207.5) 0.881
ln(TG)a 48/48 5.3 ± 0.8 5.4 ± 0.7 0.380
ln(Lip.a)c 42/43 2,89 (2.30–3.29) 3.47 (2.30–4.34) 0.052
IMT-left [mm]c 43/43 0.57 (0.51–0.66) 0.63 (0.58–0.75) 0.009
IMT-right [mm]a 40/43 0.60 ± 0.10 0.67 ± 0.15 0.013
IMT-av [mm]a 40/43 0.60 ± 0.09 0.68 ± 0.14 0.002
Glucose [mg/dl]a 48/46 88.1 ± 6.6 100.1 ± 10.8 <0.001
Insulin [μU/ml]a 46/44 8.98 ± 5.6 12.1 ± 9.7 0.069
C-Pept [ng/ml]c 38/39 2.10 (1.68–2.85) 2.70 (2.30–3.80) 0.012
HbA1c [%]a 48/47 5.3 ± 0.24 5.8 ± 0.33 <0.001
HOMA-IRa 39/39 1.95 ± 1.3 2.5 ± 1.8 0.120
QUICKIc 39/39 0.35 (0.33–0.40) 0.34 (0.31–0.38) 0.248
ln(proBNP) [pg/ml]c 43/39 3.87 (3.31–4.41) 4.14 (3.34–4.73) 0.370
ln(hsCRP) [mg/d]a 45/45 −1.97 ± 1.26 −1.90 ± 0.97 0.764
CVDb 46/45 6 (13.0) 11 (24.4) 0.188
Mean steps/7dc 38/38 6969 (5904–9092) 7707 (6145–9860) 0.747
CRP [mg/dl]c 45/45 0.14 (0.09–0.40) 0.16 (0.09–0.34) 0.904
smoking [PY]c 36/34 15.0 (0.0–27.3) 5.5 (0.0–27.8) 0.511
Bezafibrate [dd (mg)]c 14/10 400 (400–400) 400 (400–400) 0.379
Rosuvastatin [dd (mg)]c 15/23 10 (10–20) 20 (10–20) 0.394
Atorvastatin [dd (mg)]c 4/4 60 (32.5–80) 30 (17.5–50) 0.743
Simvastatin [dd (mg)]c 5/8 20 (20–20) 20 (20–80) 0.314
Ezetimibe [n(%)]b 4/5 4 (9.3) 5 (11.9) 0.697
Nicotinic Acid [n(%)]b 3/2 3 (7.0) 2 (4.8) 0.664




Data are number of observarion (n) and means ± standard deviation
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, TC total cholesterol, LDL-C low density lipoprotein cholesterol, HDL-C high density
lipiprotein cholesterol, NHDL-C non high density lipiprotein cholesterol, TG triglycerides, Lip.a lipoprotein (a), IMT carotid intima media thickness, IMT av IMT
average, C-Pept C-Peptide, HbA1c glycated haemoglobin A1c, HOMA-IR homeostatic model assessment of insulin resistance, QUICKI quantitative insulin sensitivity
check index, hsCRP high-sensitivity C-reactive protein, CVD cardiovascular disease, 7d 7 days, PY pack years, dd daily dose
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(p = 0.163). After the exclusion of patients with a history
of CV-events, HL-IGR patients still had significantly
higher carotid IMT values compared with HL-NGR pa-
tients (p = 0.044). There was an insignificant difference be-
tween the mean duration of the dyslipidemic treatment in
the HL-NGR patients compared with the HL-IGR patients
(774 days vs. 1418.50 days; p = 0.199). There was also an
insignificant difference, which is described in Table 1, in
the type and the medication dose of dyslipidemic treat-
ment received by the two groups. Additional statistical
Fig. 2 Association between average carotid IMT measurements and age (a)
Fig. 3 Box-plot for IMT average grouped by cardiovascular disease status
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analyses showed that there isn’t a significant difference be-
tween the different types of statins regarding glucose-
levels (p = 0.481) and HbA1c-levels (p = 0.511).
Discussion
This prospective cross-sectional study investigates the
differences in treated HL-IGR-patients and HL-NGR-
patients, based upon metabolic characteristics and the
IMT.
The main findings in our study were the significantly
higher measurements of the IMT in HL-IGR patients, as
well as a higher occurrence of a subclinical carotid-
atherosclerosis, which was defined as a cut-off value of
≥0,8 mm [2]. HL-IGR patients also showed a signifi-
cantly higher degree of central obesity, especially in the
waist circumference compared to HL-NGR patients. In
addition we observed an association between the IMT
and age in treated dyslipidemic patients.
However literature about hyperlipidemic patients with
screen-detected impaired glucose regulation especially
regarding atherosclerosis is sparse. In general it is known
that hyperlipidemia and hyperglycemia [18–21] are both
risk-factors of atherosclerosis on their own, but there are
no studies which have investigated the combined effect
of these two factors. In our study HL-IGR patients have
a higher IMT than HL-NGR patients and also more
often an insignificant stenosis which could indicate a cu-
mulative effect. However our study groups had an imbal-
anced mean age and it is well known that age is also a
predictor of atherosclerosis [18]. Nevertheless we think
that especially in elderly hyperlipidemic patients, the
screening for IGR may be important, not only concern-
ing the higher risk of atherosclerosis but also other
complications. To clarify this issue it is necessary to
investigate in larger studies whether the specific popula-
tion of HL-IGR patients could benefit from an additional
antihyperglycemic treatment in addition to the antilipi-
demic treatment in order to prevent the progression of
atherosclerosis.
Another interesting but yet unresolved issue is the po-
tential association between fasting plasma glucose and
IMT in hyperlipidemic patients. The currently existing
data is controversial regarding this topic [18, 22, 23]. A
relationship could also be based on shared risk factors
and nonglucose pathways [24, 25].
On the other hand our study results confirm the exist-
ing data and show that there is an independent positive
correlation of age and the IMT [26, 27]. This results
point out that antilipidemic treatment cannot curb this
correlation.
In contrast to the study of Salonen et al. [26] we were
unable to find a correlation between smoking and the pro-
gression of atherosclerosis in the IMT of treated dyslipid-
emic patients. Our finding that HL-IGR patients have a
significantly higher degree of central obesity, especially in
the waist circumference confirms the close relationship
between abdominal Obesity and Prediabetes [28]. Add-
itional statistical analyses confirmed this assumption and
showed that there is a significant correlation between
waist circumference and insulin resistance.
HL-IGR patients in our study have higher insulin
values compared with HL-NGR-patients reflecting more
pronounced insulin resistance. Indeed HL-IGR patients
have a greater tendency for insulin resistance calculated
by the HOMA-formula compared to HL-NGR patients.
In the study of Kostapanos et al., the investigators
showed that longtime statin-dosage can aggravate
insulin-resistance in hyperlipidemic-patients with im-
paired fasting glucose [29] and our results point out that
HL-IGR patients had more often and for a longer dur-
ation an antilipidemic statin-treatment, compared to
HL-NGR patients and also a significantly higher waist
circumference which is a marker of insulin resistance
[28]. However we couldn’t found significant differences
between the different types of statin-treatment regarding
glucose-levels and HbA1c-levels. Nevertheless there is
also controversial data available which show that statins
don’t have a diabetogenic effect [30, 31]. HL-IGR-
patients in our study have significantly higher fasting-
glucose-levels and thus also the impact of statin therapy
on glucose metabolism has to be considered. Prediabetes
is also a factor associated with mortality as shown in the
Decode study [32].
Furthermore the sub-analysis that hyperlipidemic pa-
tients in our study, who had a cardiovascular event in
the past have significantly higher IMT-measurements
compared to those without and that CVD-status in
treated hyperlipidemic patients is an independent vari-
able which explains the IMT, confirms existing studies
and is in line with a meta-analysis of Lorenz et al., who
also showed that the IMT is directly associated with the
occurence of cardiovascular events [33].
Nevertheless additional statistical analyses of our data
showed that after the exclusion of patients with a history
of cardiovascular events, HL-IGR patients still had sig-
nificantly higher carotid IMT measures compared with
HL-NGR patients (p = 0.044). This data shows that there
is a cumulative effect of dyslipidemia and IGR which has
been rarely examined up to now.
In our study there was no correlation between the
lipid levels (LDL-cholesterol, TC, HDL-cholesterol) and
the carotid intima media thickness. This lack of associ-
ation could be explained by the fact that all of the study
participants had lipid-lowering treatment when they en-
tered the study. Nevertheless it would be necessary to
prove in larger studies if HL-IGR patients can benefit of
a more strict and exact antilipidemic treatment, as previ-
ously shown in the JART study in which patients with a
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strictly treated LDL-cholesterol level of >100 mg/dl and
<120 mg/dl for one year showed a reduction of athero-
sclerosis by 4.29 % (0.040 mm) [34] as well as to prove if
HL-IGR patients can benefit of an additional antihyper-
glycaemic treatment in order to decrease the risk for the
progression of atherosclerosis.
A suggestion of the authors of this study regarding
antihyperglycaemic treatment in HL-IGR patients is to
encourage life-style modification with an improvement
in nutrition and increase of physical activity according
to the Austrian Diabetes Association guidelines [35].
Physical activity should be increased to 30 min per day
or a minimum of 150 min per week. In addition, as rec-
ommended by the American Diabetes Association, early
oral antihyperglycaemic drug therapy with metformin
could be helpful in the high-risk population of HL-IGR-
patients in order to decrease the risk of comorbidities,
especially for atherosclerosis [36]. The recently pre-
sented EMPA-REG study is the first study which shows
that diabetic patients who received the SGLT-2 inhibitor
empagliflozin had a significantly lower risk of death of
cardiovascular events compared with a placebo group
[37]. Research indicates that empagliflozin in addition to
conservative treatment could be even more useful in
HL-IGR- patients than metformin, especially regarding
the high risk of atherosclerosis in this specific popula-
tion. However more research needs to be done because
no studies investigated the potential impact of empagli-
flozin in hyperlipidemic patients additionally affected by
prediabetes up to now.
Our study has some limitations: The most important
limitation of our study is the differences in the mean age
between the two study groups. In addition to the small
number of participants our results are restricted due to
the definition of IGT by using fasting blood samples and
HbA1c and not the oral glucose tolerance test (OGTT)
[38]. In addition some data from our study groups was
missing, and the two groups received different treatment
modalities.
Conclusion
We summarize, that HL-IGR-patients in comparison
to HL-NGR-patients are characterised as being older,
having a higher risk of atherosclerosis and may need
in addition to an optimal antilipidemic- also an
antihyperglycemic treatment to prevent cardiovascular
disease and progressive atherosclerosis. Prospective
studies with a larger number of participants and dif-
ferent age-groups would be necessary in order to get
more conclusive results. A recommendation of our
study is that HL-IGR-patients need more frequent in-
vestigations (e.g. blood tests, IMT measurement) and
that the medication should be adjusted at regular
follow up-appointments.
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